Personalized peptide vaccination: A novel immunotherapeutic approach for advanced cancer

References

• van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254:1643 - 7; http://dx.doi.org/10.1126/science.1840703; PMID: 1840703
   PubMed Web of Science ®Google Scholar
• Schlom J. Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst 2012; 104:599 - 613; http://dx.doi.org/10.1093/jnci/djs033; PMID: 22395641
   PubMed Web of Science ®Google Scholar
• Sharma P, Wagner K, Wolchok JD, Allison JP. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer 2011; 11:805 - 12; http://dx.doi.org/10.1038/nrc3153; PMID: 22020206
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al, IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411 - 22; http://dx.doi.org/10.1056/NEJMoa1001294; PMID: 20818862
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711 - 23; http://dx.doi.org/10.1056/NEJMoa1003466; PMID: 20525992
   PubMed Web of Science ®Google Scholar
• Sasada T, Komatsu N, Suekane S, Yamada A, Noguchi M, Itoh K. Overcoming the hurdles of randomised clinical trials of therapeutic cancer vaccines. Eur J Cancer 2010; 46:1514 - 9; http://dx.doi.org/10.1016/j.ejca.2010.03.013; PMID: 20413296
   PubMed Web of Science ®Google Scholar
• Eggermont AM. Therapeutic vaccines in solid tumours: can they be harmful?. Eur J Cancer 2009; 45:2087 - 90; http://dx.doi.org/10.1016/j.ejca.2009.05.004; PMID: 19477117
   PubMed Web of Science ®Google Scholar
• Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15:5323 - 37; http://dx.doi.org/10.1158/1078-0432.CCR-09-0737; PMID: 19723653
   PubMed Web of Science ®Google Scholar
• Chen W, McCluskey J. Immunodominance and immunodomination: critical factors in developing effective CD8+ T-cell-based cancer vaccines. Adv Cancer Res 2006; 95:203 - 47; http://dx.doi.org/10.1016/S0065-230X(06)95006-4; PMID: 16860659
   PubMed Web of Science ®Google Scholar
• Mochizuki K, Sato Y, Tsuda N, Shomura H, Sakamoto M, Matsuura K, et al. Immunological evaluation of vaccination with pre-designated peptides frequently selected as vaccine candidates in an individualized peptide vaccination regimen. Int J Oncol 2004; 25:121 - 31; PMID: 15201997
   PubMed Web of Science ®Google Scholar
• Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 2011; 331:1565 - 70; http://dx.doi.org/10.1126/science.1203486; PMID: 21436444
   PubMed Web of Science ®Google Scholar
• Itoh K, Yamada A. Personalized peptide vaccines: a new therapeutic modality for cancer. Cancer Sci 2006; 97:970 - 6; http://dx.doi.org/10.1111/j.1349-7006.2006.00272.x; PMID: 16984371
   PubMed Web of Science ®Google Scholar
• Itoh K, Yamada A, Mine T, Noguchi M. Recent advances in cancer vaccines: an overview. Jpn J Clin Oncol 2009; 39:73 - 80; http://dx.doi.org/10.1093/jjco/hyn132; PMID: 19015149
   PubMed Web of Science ®Google Scholar
• Yoshida K, Noguchi M, Mine T, Komatsu N, Yutani S, Ueno T, et al. Characteristics of severe adverse events after peptide vaccination for advanced cancer patients: Analysis of 500 cases. Oncol Rep 2011; 25:57 - 62; PMID: 21109957
   PubMed Web of Science ®Google Scholar
• Whiteside TL. Immune monitoring of clinical trials with biotherapies. Adv Clin Chem 2008; 45:75 - 97; http://dx.doi.org/10.1016/S0065-2423(07)00004-2; PMID: 18429494
   PubMed Web of Science ®Google Scholar
• Noguchi M, Mine T, Komatsu N, Suekane S, Moriya F, Matsuoka K, et al. Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination. Cancer Biol Ther 2011; 10:1266 - 79; PMID: 20935522
   PubMed Web of Science ®Google Scholar
• Komatsu N, Shichijo S, Nakagawa M, Itoh K. New multiplexed flow cytometric assay to measure anti-peptide antibody: a novel tool for monitoring immune responses to peptides used for immunization. Scand J Clin Lab Invest 2004; 64:535 - 45; http://dx.doi.org/10.1080/00365510410007008; PMID: 15370458
   PubMed Web of Science ®Google Scholar
• Noguchi M, Kakuma T, Uemura H, Nasu Y, Kumon H, Hirao Y, et al. A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. Cancer Immunol Immunother 2010; 59:1001 - 9; http://dx.doi.org/10.1007/s00262-010-0822-4; PMID: 20146063
   PubMed Web of Science ®Google Scholar
• Terasaki M, Shibui S, Narita Y, Fujimaki T, Aoki T, Kajiwara K, et al. Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen--A24 with recurrent or progressive glioblastoma multiforme. J Clin Oncol 2011; 29:337 - 44; http://dx.doi.org/10.1200/JCO.2010.29.7499; PMID: 21149665
   PubMed Web of Science ®Google Scholar
• Disis ML. Immunologic biomarkers as correlates of clinical response to cancer immunotherapy. Cancer Immunol Immunother 2011; 60:433 - 42; http://dx.doi.org/10.1007/s00262-010-0960-8; PMID: 21221967
   PubMed Web of Science ®Google Scholar
• Hoos A, Eggermont AM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 2010; 102:1388 - 97; http://dx.doi.org/10.1093/jnci/djq310; PMID: 20826737
   PubMed Web of Science ®Google Scholar
• Amos SM, Duong CP, Westwood JA, Ritchie DS, Junghans RP, Darcy PK, et al. Autoimmunity associated with immunotherapy of cancer. Blood 2011; 118:499 - 509; http://dx.doi.org/10.1182/blood-2011-01-325266; PMID: 21531979
   PubMed Web of Science ®Google Scholar
• López MN, Pereda C, Segal G, Muñoz L, Aguilera R, González FE, et al. Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells. J Clin Oncol 2009; 27:945 - 52; http://dx.doi.org/10.1200/JCO.2008.18.0794; PMID: 19139436
   PubMed Web of Science ®Google Scholar
• Komatsu N, Matsueda S, Tashiro K, Ioji T, Shichijo S, Noguchi M, et al. Gene expression profiles in peripheral blood as a biomarker in cancer patients receiving peptide vaccination. Cancer 2011; PMID: 22071976
   PubMed Web of Science ®Google Scholar
• Yoshiyama K, Terazaki Y, Matsueda S, Shichijo S, Noguchi M, Yamada A, et al. Personalized peptide vaccination in patients with refractory non-small cell lung cancer. Int J Oncol 2012; 40:1492 - 500; PMID: 22307435
   PubMed Web of Science ®Google Scholar
• Yoshitomi M, Yutani S, Matsueda S, Ioji T, Komatsu N, Shichijo S, et al. Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status, and pre-existing antigen-specific immunity as possible biomarkers for patient prognosis. Exp Ther Med 2012; 3:463 - 9
   PubMed Web of Science ®Google Scholar
• Sansone P, Bromberg J. Targeting the interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol 2012; 30:1005 - 14; http://dx.doi.org/10.1200/JCO.2010.31.8907; PMID: 22355058
   PubMed Web of Science ®Google Scholar